What To Expect From USPTO On Patent Term Post-Supernus

"Though it remains to be seen when and how the USPTO will address, codify and apply Supernus, its treatment of Novartis provides some predictive value with respect to its future approach. In the interim, it may behoove patentees to identify their Supernus-eligible patents and consider whether a PTA petition is warranted."Kamps, schwartz, eckerley, law360